Skip to main content
Devonian Health Group Inc logo

Devonian Health Group Inc — Investor Relations & Filings

Ticker · GSD ISIN · CA2518341078 TSXV Manufacturing
Open in API
Filings indexed 598 across all filing types
Latest filing 2023-05-17 Regulatory Filings
Country CA Canada
Listing TSXV GSD

About Devonian Health Group Inc

https://groupedevonian.com/

Devonian Health Group Inc. is a clinical-stage botanical pharmaceutical company specializing in the development of novel prescription therapeutic solutions for unmet medical needs. The core business involves late-stage prescription botanical drugs targeting fibroinflammatory autoimmune diseases, with a focus on gastrointestinal, dermatological, and hepatologic conditions. The company utilizes a broad-based technology platform, originating from over 20 years of research, to develop therapies that target multiple cellular pathways and regulate genes linked to these diseases. Its pipeline includes the lead product candidate, Thykamine, currently in Phase 3 clinical trials. Devonian also develops high-value dermatological products alongside its core drug development activities.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings
2023-05-17 English
News release - English.pdf
Regulatory Filings
2023-05-16 English
News release - French.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of new members to the board of directors and the granting of stock options. It details the backgrounds of the new directors and the terms of the stock options granted. There is no financial data, no detailed report, no earnings information, and no regulatory filing of financial results. The content focuses on management and board changes and related governance matters. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is sufficient and the content is substantive, not just a brief announcement or a report publication notice.
2023-05-12 English
News release - English.pdf
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of new board members and the grant of stock options to directors and consultants. It focuses on changes in the company's board of directors and management personnel. There is no financial data, earnings information, or detailed report content. The primary subject is management changes and related corporate governance matters. Therefore, the document fits best under the category for announcements of changes in the company's board or senior management, which is 'Board/Management Information' (MANG). The document length and content confirm it is not a brief announcement or a regulatory filing but a substantive announcement of management changes.
2023-05-12 English
News release - English.pdf
Regulatory Filings
2023-05-11 English
Decision Document (Preliminary).pdf
Regulatory Filings Classification · 95% confidence The document is a visa (approval) notice from the Autorité des marchés financiers regarding a preliminary prospectus dated May 10, 2023. It references regulatory compliance and approval for a prospectus filed under securities regulations across multiple Canadian provinces. The document is short (1394 characters) and serves as an official regulatory approval notice rather than the prospectus itself or a financial report. There is no financial data, management discussion, or detailed report content. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-05-10 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.